Gila Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $402K
Latest Deal Amount
  • Investors
  • 5

Gila Therapeutics General Information

Description

Operator of a clinical-stage pharmaceutical company designed to treat obesity and prevent weight gain. The company develops and commercializes innovative, effective and safe therapies for metabolic diseases, using novel routes of administration, enabling people to lose weight and decrease calorie intake in a non-invasive and non-absorbed manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 5420 Highwood Drive West
  • Minneapolis, MN 55436
  • United States
+1 (612) 000-0000

Gila Therapeutics Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gila Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 16-Feb-2021 $402K 000 Completed Clinical Trials - Phase 1
4. Later Stage VC 00000 00.00 Completed Generating Revenue
3. Early Stage VC (Series A) 11-Mar-2019 00000 00.000 Completed Generating Revenue
2. Accelerator/Incubator $4M Completed Generating Revenue
1. Early Stage VC (Series A) 02-Mar-2017 $4M $4M 000.00 Completed Generating Revenue
To view Gila Therapeutics’s complete valuation and funding history, request access »

Gila Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
To view Gila Therapeutics’s complete cap table history, request access »

Gila Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Scott Schorer Chief Executive Officer, Board Member & President
Jon Freeman Chief Financial Officer
Thomas Vasicek Ph.D Co-Founder & Chairman
Andres Acosta MD Co-Founder
You’re viewing 4 of 5 executive team members. Get the full list »

Gila Therapeutics Board Members (3)

Name Representing Role Since
Christopher DeSouza Self Board Member 000 0000
Richard Horan Self Board Member 000 0000
Thomas Vasicek Ph.D Gila Therapeutics Co-Founder & Chairman 000 0000
To view Gila Therapeutics’s complete board members history, request access »

Gila Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gila Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Argonautic Ventures Venture Capital Minority 000 0000 000000 0
Broadview Ventures Venture Capital Minority 000 0000 000000 0
Harvard Business School Alumni Angels of Chicago Angel Group Minority 000 0000 000000 0
iSelect Fund Venture Capital Minority 000 0000 000000 0
Lagomaj Capital Venture Capital Minority 000 0000 000000 0
To view Gila Therapeutics’s complete investors history, request access »